贵州医科大学学报

2018, v.43;No.212(05) 599-603

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

替吉奥联合NP方案化疗对转移性乳腺癌患者部分肿瘤标志物及雌激素水平的影响
Effect of S-1 Combined with Routine Chemotherapy on Level of Estrogen and Tumor Marker in Metastatic Breast Cancer Patients

赵建昌;
ZHAO Jianchang;Hematology and Oncology Department,People's Hospital of Chongzhou;

摘要(Abstract):

目的:探讨替吉奥联合NP方案化疗对转移性乳腺癌患者癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原153(CA153)、恶性肿瘤特异性生长因子(TSGF)及黄体生成素(LH)、雌二醇(E2)水平的影响。方法:84例转移性乳腺癌患者,根据化疗方案均分为对照组和观察组,对照组患者采用NP标准方案化疗,观察组患者采用替吉奥联合NP方案化疗,4周为1周期、共2个周期;比较2组患者治疗前后生存质量测评量表(FACT-B)评分、血清CEA、CA125、CA153、TSGF、LH及E2的变化;治疗后随访半年、1年及2年,记录近期临床疗效、远期生存率及治疗期间的不良反应。结果:与治疗前比较,治疗后对照组FACT-B评分较治疗前降低(P<0.05),观察组FACT-B评分较治疗前升高(P<0.01);治疗后2组患者血清CEA、CA125、CA153、TSGF、LH及E2水平降低,观察组降低更明显(P<0.01);治疗后观察组总有效率(RR)为66.67%,显著高于对照组(35.71%),差异有统计学意义(P<0.01);观察组治疗后半年生存率与对照组比较差异无统计学意义(P>0.05),治疗后1年及2年生存率明显高于对照组(P<0.05或P<0.01),2组患者治疗期间均无严重不良反应发生。结论:替吉奥联合NP方案治疗转移性乳腺癌症近远期疗效优于单一NP方案治疗,可明显降低血清肿瘤标志分子及雌激素水平。
Objective: To investigate the effect of S-1 combined with routine chemotherapy on the level of tumor marker molecules( CEA,CA125,CA153,TSGF,LH and E2) in the treatment of metastatic breast cancer patients. Methods: A total of 84 metastatic breast cancer patients were selected and divided into study group( n = 42) and control group( n = 42) according to the chemotherapy regimen. The control group was treated with NP standard chemotherapy regimen. The study group was treated with S-1 on the basis of the control group,4 weeks for 1 cycle,a total of 2 cycles of treatment.Comparing statistics before and after treatment of the adverse reactions,recent and long-term clinical efficacy of half a year,one year and two years of the 2 groups,the quality of life,serum changes of CEA,CA125,CA153,TSGF,LH and E2. Results: After treatment,the CEA,CA125,CA153,TSGF,LH and E2 levels in both groups were lower than before treatment,and the study group was lower than that of the control group( P < 0. 01). FACT-B scores of control group was lower after treatment( P < 0. 05),study group FACT-B scores increased( P < 0. 01). The total effective rate of the study group was 66. 67%,which was significantly higher than 35. 71% of the control group,differences were statistically significant( P < 0. 01). The 1-year and 2-year survival rates after treatment were significantly higher in the study group than in the control group( P < 0. 05 or P < 0. 01). No severe adverse reactions were found in both groups. Conclusion: S-1 combined with NP in the treatment of metastatic breast cancer has batter near and long-term effect,significantly reduce serum tumor marker molecules and estrogen levels.

关键词(KeyWords): 乳腺肿瘤;肿瘤转移;替吉奥;肿瘤标志分子;雌激素;预后
breast cancer;tumor metastasis;teggio;tumor marker molecule;estrogen;prognosis

Abstract:

Keywords:

基金项目(Foundation): 四川省卫生厅基金项目(16PJ447)

作者(Author): 赵建昌;
ZHAO Jianchang;Hematology and Oncology Department,People's Hospital of Chongzhou;

Email:

DOI: 10.19367/j.cnki.1000-2707.2018.05.022

参考文献(References):

文章评论(Comment):

序号(No.) 时间(Time) 反馈人(User) 邮箱(Email) 标题(Title) 内容(Content)
反馈人(User) 邮箱地址(Email)
反馈标题(Title)
反馈内容(Content)
扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享